1404456-53-6
1404456-53-6 structure
- Name: GSK 2830371
- Chemical Name: (S)-5-{[(5-chloro-2-methylpyridin-3-yl)amino]methyl}-N-[3-cyclopentyl-1-(cyclopropylamino)-1-oxopropan-2-yl]thiophene-2-carboxamide
- CAS Number: 1404456-53-6
- Molecular Formula: C23H29ClN4O2S
- Molecular Weight: 461.020
- Catalog: Biochemical Inhibitor Angiogenesis Others
- Create Date: 2016-01-08 13:01:58
- Modify Date: 2024-01-13 15:05:05
-
GSK 2830371 is a highly selective Wip1 phosphatase inhibitor with IC50 of 6 nM.
| Name | (S)-5-{[(5-chloro-2-methylpyridin-3-yl)amino]methyl}-N-[3-cyclopentyl-1-(cyclopropylamino)-1-oxopropan-2-yl]thiophene-2-carboxamide |
|---|---|
| Synonyms |
gsk 2830371
2-Thiophenecarboxamide, 5-[[(5-chloro-2-methyl-3-pyridinyl)amino]methyl]-N-[(1S)-1-(cyclopentylmethyl)-2-(cyclopropylamino)-2-oxoethyl]- 5-{[(5-Chloro-2-methyl-3-pyridinyl)amino]methyl}-N-[(2S)-3-cyclopentyl-1-(cyclopropylamino)-1-oxo-2-propanyl]-2-thiophenecarboxamide gsk2830371 |
| Description | GSK 2830371 is a highly selective Wip1 phosphatase inhibitor with IC50 of 6 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 6 nM (Wip1 phosphatase)[1] |
| In Vitro | GSK 2830371 potently inhibits Wip1 (2-420) dephosphorylation of FDP and the endogenous substrates phospho-p38 MAPK (T180) with IC50 values of 6 nM and 13 nM, respectively. In the PPM1D-amplified MCF7 breast carcinoma cells, treatment with GSK 2830371 (0.04, 0.11, 0.33, 1, 3, and 9 μM) increased phosphorylation of substrates in a concentration-dependent manner. Treatment of MX-1 and MCF7 cells (Wip1amplified, p53 wild type) with GSK 2830371 (0.001, 0.01, 0.1, 1, and 10 μM) causes concentration-dependent effects in cell growth assays[1]. GSK2830371 has a 50% growth inhibitory concentration (GI50) of 2.65 μM±0.54 (SEM) in MCF-7 cells. Treatment of MCF-7 cells with 2.5μM GSK2830371 results in marked time-dependent degradation of both isoforms of WIP1 over 8 hours which correlated with p53 stabilisation and phospho-p53Ser15 (pp53Ser15)[2]. |
| In Vivo | In a pharmacodynamic assay, orally administered GSK 2830371 increases phosphorylation of Chk2 (T68) and p53 (S15) and decreased Wip1protein concentrations in DOHH2 tumors. Following 14 d of oral dosing at 150 mg per kg body weight, BID (twice daily) and TID (thrice daily), GSK 2830371 inhibits the growth of DOHH2 tumor xenografts by 41% and 68%, respectively. Comparable tumor growth inhibition is observed in mice treated BID with either 75 or 150 mg per kg body weight. Greater tumor growth inhibition with the TID schedule is consistent with a short half-life of GSK 2830371 in mice and suggests that sustained inhibition of Wip1 may be required for maximal antitumor effect[1]. |
| Kinase Assay | The primary in vitro Wip1 enzymatic assay measured fluorescence generated by Wip-1 (2-420) hydrolysis of fluorescein diphosphate (FDP). 50 μM FDP substrate is added with GSK 2830371 or DMSO at room temperature before addition of 10 nM Wip1 in assay buffer (50 mM TRIS, pH 7.5, 30 mM MgCl2, 0.8 mM CHAPS, 0.05 mg/mL BSA). Fluorescent signal is detected on a Spectramax microplate reader (485/530 nm)[1]. |
| Cell Assay | Cells are seeded into 96 well plates at 200-400 cells per well and treated with GSK 2830371 dilution series on day 1. After 7 d, we used the CellTiter-Glo cell viability assay to determine effects on cell growth. Luminescent signal is detected on an EnVision 2104. For clonogenic assays, cells are seeded in 12-well tissue culture plates at 2,000 cells per well. Cells are treated with a compound dilution series on day 1 and again on day 7. After 14 d, cells are washed with 1× PBS, stained with 1 mL of Coomassie Brilliant Blue R-250, and colonies are quantitated with the Optomax Sorcerer colony counter[1]. |
| Animal Admin | Mice[1] Female SCID mice are subcutaneously inoculated with 1×107 DOHH2 cells and tumor growth is monitored with electronic calipers. When tumors reached 100-200 mm3, animals are treated orally twice (BID) or thrice (TID) daily with vehicle (2% DMSO and 40% Captisol, pH 4.0) or GSK 2830371. For efficacy studies, eight mice per group are administered with GSK 2830371 at 75 or 150 mg per kg body weight BID or 150 mg per kg body weight TID. Tumor growth inhibition (% difference in tumor growth compared to control) is calculated when tumors for vehicle-control mice exceeded 1,000 mm3 (day 11). For pharmacodynamic biomarker analysis, DOHH2 tumors from three mice are harvested 2 or 4 h after final dose following 14 d of treatment with either vehicle or GSK 2830371 at 75 or 150 mg per kg body weight, BID; tumors are frozen in liquid nitrogen for subsequent lysis and western blot analysis. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 704.1±60.0 °C at 760 mmHg |
| Molecular Formula | C23H29ClN4O2S |
| Molecular Weight | 461.020 |
| Flash Point | 379.7±32.9 °C |
| Exact Mass | 460.169983 |
| PSA | 111.36000 |
| LogP | 3.41 |
| Appearance | white to beige |
| Vapour Pressure | 0.0±2.2 mmHg at 25°C |
| Index of Refraction | 1.623 |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: soluble20mg/mL, clear |
| RIDADR | NONH for all modes of transport |
|---|